about
Future directions for bone metastasis research - highlights from the 2015 bone and the Oncologist new updates conference (BONUS)Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analysesActivation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysisPrognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysisPrognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysisp53 Arg72Pro polymorphism, HPV status and initiation, progression, and development of cervical cancer: a systematic review and meta-analysisCardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational studyRelevance of randomised controlled trials in oncology.Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations.Clinical trial design in biosimilar drug development.Chemotherapy treatment decision-making experiences of older adults with cancer, their family members, oncologists and family physicians: a mixed methods study.Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone.Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials.Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases.Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis.Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients.Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial.Extended adjuvant tamoxifen for early breast cancer: a meta-analysis.Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in CanadaOutcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer.Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy.Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meetingImpact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel.Does estrogen play a role in response to adjuvant bone-targeted therapies?Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers.Bone-targeted therapy for metastatic breast cancer-Where do we go from here? A commentary from the BONUS 8 meeting.Prevalence of overt metastases in locally advanced breast cancer.Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancerEvaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapyAdjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients.Neuregulin expression in solid tumors: prognostic value and predictive role to anti-HER3 therapies.Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis.Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.Antivascular agents for non-small-cell lung cancer: current status and future directions.A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer.
P50
Q26747566-936E18A0-6FFC-4B0D-BFCE-7C86BF86DDCEQ26786243-3EA07A5B-B416-424C-8472-4CB5859DD380Q26830671-64324022-78C7-4DED-9B59-4E8748869DB0Q27001079-A7670AAC-FECF-401C-B9EC-C0C7DEE59216Q27022482-A995A38C-1AFD-43B0-9474-06F591D8FA1BQ27022986-30B8AFFF-49E1-43B7-AFEA-07B2F828FC5BQ28545130-F64D3AA9-09A5-4D01-AAA0-88F3D3785D7EQ30240233-756F5B71-8B5A-4C85-86C7-20476C072E26Q30406304-BF886597-9FD8-4A41-A599-811CA26F7D35Q30423748-94B7B811-9972-410B-AD60-9E44350979D6Q30836526-E27D42F4-E9F9-4C71-BEF0-64C49BE04C8DQ30878925-0D08F4A9-BC89-4DE0-8984-C7EC7AA93107Q33739392-7ADD5314-D0F2-4E39-875D-0F4EF3275788Q33785011-4E352094-3FF1-465E-9873-648B5971695EQ34325491-1B9E7D70-44BF-463D-9AF1-51EC1207BF57Q34637757-F5916C62-2BED-40E3-B9E8-817AA0DD43C1Q35006851-68B86B54-4DC8-480A-9DED-8789315E056FQ35086832-CFFF32CB-4271-4E6B-8F93-6F83FECFD5BEQ35106041-3B332606-685A-4503-B491-900B0AB7CB3BQ35445037-387DA617-2D49-40B4-97A7-BEDBB7B8F7E8Q35687851-9C5FC3ED-9E40-4B0A-8053-7B2234D5C086Q35939172-EE4F1B2B-9A82-4621-B978-EBC4121119B8Q35963154-7EC5E55D-6943-4BBE-92BA-70869561E160Q36093774-274D7836-5094-4E48-BBEF-6106B90D979EQ36207662-148C34FA-88FB-41F9-B9C4-AA5AF050419AQ36490409-D83102F7-9BA8-433E-AE56-1F181F2796BFQ36491529-9689241E-C753-49FF-947E-4327344BD317Q36491554-300AA561-BF94-4C7D-AD1F-3AE836E53EF4Q36491642-0D087A96-B4C9-45DD-BA0A-414D22FB1FCDQ37141604-7CCF8678-5508-4F7F-87B9-AD98B6A23D00Q37240839-2FDF3597-2909-443A-B772-99510CC2DD55Q37278502-3831932A-C89A-4DDE-A96B-A35CF3FC163AQ37420996-5DFB5E60-937A-42FB-A689-BF6AF639928CQ37529516-3E2A5EAC-82C5-4D18-A192-A2D5C5D02E44Q37564335-3515938F-938B-4111-B263-FACEF84874E2Q37566328-F18B8EAC-886A-4091-81E0-21BB0AEEE677Q37592627-15EF82DA-2349-404E-9D35-89560DB2356CQ37624732-91CD3BE5-D265-4AD3-8560-0091023B77E5Q37656386-82F33BE0-16F8-455E-913F-EB132872C41EQ37681170-2B7DFC5B-27F8-47C8-B621-C8DCCC861295
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Eitan Amir
@ast
Eitan Amir
@en
Eitan Amir
@es
Eitan Amir
@nl
Eitan Amir
@sl
type
label
Eitan Amir
@ast
Eitan Amir
@en
Eitan Amir
@es
Eitan Amir
@nl
Eitan Amir
@sl
prefLabel
Eitan Amir
@ast
Eitan Amir
@en
Eitan Amir
@es
Eitan Amir
@nl
Eitan Amir
@sl
P106
P1153
24066421000
P2038
Eitan_Amir
P21
P214
1767147665809260670009
P31
P3835
eitan-amir
P496
0000-0002-3706-525X
P569
2000-01-01T00:00:00Z
P734
P735
P7859
lccn-no2013081596